JGC
PCVX icon

J. Goldman & Co’s Vaxcyte PCVX Stock Holding History

J. Goldman & Co’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-27,000
Closed -$1.29M – 450
2022
Q4 		$1.29M Sell
27,000
-40,500
-60% -$1.59M 0.06% 202
2022
Q3 		$1.62M Buy
+67,500
New +$1.71M 0.08% 226

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's PCVX Position: Q3 2024 in Review

J. Goldman & Co sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 2,700 shares — an estimated $204K sold.

J. Goldman & Co first reported a position in PCVX in Q3 2022 and held it in 7 quarters. The position peaked at $1.78M in Q4 2022. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • J. Goldman & Co reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 2,700 Vaxcyte shares in Q3 2024, an estimated $204K.
  • J. Goldman & Co first reported a position in Vaxcyte in Q3 2022 and held it in 7 quarters.
  • J. Goldman & Co's Vaxcyte position peaked at $1.78M in Q4 2022.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.